The purpose of this study is to assess the effects of rosuvastatin compared to usual care in patients diagnosed with aortic valvular stenosis. Patients must have a diagnosis of mild to moderate aortic stenosis (AS) and no clinical indication for the use of cholesterol lowering agents. A multi-centre, randomized, double-blind, placebo-controlled study, with a two year recruitment period, and a treatment duration of a minimum of 3 years from the time of the last patient randomized to a maximum of 5 years.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
378
40 mg, oral, single dose
oral, single dose
Research site
Calgary, Alberta, Canada
Research site
Edmonton, Alberta, Canada
Research site
Surrey, British Columbia, Canada
The changes in transvalvular aortic velocities and the changes in aortic valve area.
Time frame: Between baseline and close-out measurments.
The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups.
Time frame: Baseline and minimum of 3 year follow-up.
The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups.
Time frame: Between baseline and close-out measurments.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research site
Vancouver, British Columbia, Canada
Research site
Victoria, British Columbia, Canada
Research site
Edmonton, Manitoba, Canada
Research site
Brampton, Ontario, Canada
Research site
Cambridge, Ontario, Canada
Research site
Kitchener, Ontario, Canada
Research site
Montreal, Ontario, Canada
...and 5 more locations